Literature DB >> 22495176

MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type.

Anne Pham-Ledard, David Cappellen, Fabian Martinez, Béatrice Vergier, Marie Beylot-Barry, Jean-Philippe Merlio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22495176     DOI： 10.1038/jid.2012.102

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  14 in total

1.  Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.

Authors:  Lianne Koens; Willem H Zoutman; Passorn Ngarmlertsirichai; Grzegorz K Przybylski; Piotr Grabarczyk; Maarten H Vermeer; Rein Willemze; Patty M Jansen; Christian A Schmidt; Cornelis P Tensen
Journal:  J Invest Dermatol       Date:  2013-06-13       Impact factor: 8.551

2.  MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.

Authors:  C Fernández-Rodríguez; B Bellosillo; M García-García; B Sánchez-González; E Gimeno; M C Vela; S Serrano; C Besses; A Salar
Journal:  Leukemia       Date:  2014-06-06       Impact factor: 11.528

Review 3.  Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

Authors:  Richard Rosenquist; Andreas Rosenwald; Ming-Qing Du; Gianluca Gaidano; Patricia Groenen; Andrew Wotherspoon; Paolo Ghia; Philippe Gaulard; Elias Campo; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

Review 4.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

5.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

Review 6.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

7.  Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Authors:  Priscilla N Kelly; Donna L Romero; Yibin Yang; Arthur L Shaffer; Divya Chaudhary; Shaughnessy Robinson; Wenyan Miao; Lixin Rui; William F Westlin; Rosana Kapeller; Louis M Staudt
Journal:  J Exp Med       Date:  2015-11-30       Impact factor: 14.307

8.  Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No MYD88 Mutation by Padlock Probe Hybridization.

Authors:  Yukiko Nishi; Riko Kitazawa; Ryuma Haraguchi; Ayaka Ouchi; Yasuo Ueda; Yuri Kamaoka; Ken Yamamoto; Yasuhiko Todo; Hiroaki Miyaoka; Sohei Kitazawa
Journal:  Case Rep Oncol       Date:  2017-06-14

9.  The role of molecular pathology in the diagnosis of cutaneous lymphomas.

Authors:  Philipp W Raess; Adam Bagg
Journal:  Patholog Res Int       Date:  2012-11-19

10.  Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.

Authors:  Lucy C Fox; Costas K Yannakou; Georgina Ryland; Stephen Lade; Michael Dickinson; Belinda A Campbell; Henry Miles Prince
Journal:  Int J Mol Sci       Date:  2018-06-13       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.